Synoligo Biotechnologies and Lumiphore Forge a New Era in Nucleic Acid Testing

A Transformative Collaboration in Diagnostics

In a significant move for the nucleic acid amplification testing (NAAT) market, Synoligo Biotechnologies Inc. and Lumiphore Inc. have announced a new partnership focused on integrating Lumiphore’s cutting-edge luminescent lanthanide reporter technology with Synoligo's oligonucleotide offerings. This collaboration aims to enhance diagnostic tests and life science research through innovative applications of time-resolved Förster resonance energy transfer (TR-FRET) assays.

Synoligo, based in Morrisville, North Carolina, is recognized as a frontrunner in manufacturing Dual Labeled Quenched Probes. The company’s strategic collaboration with Lumiphore is expected to leverage lanthanide technology for real-time genomic applications, setting a new standard in the industry.

The Science Behind the Innovation

At the heart of this collaboration lies the patented Lumi804-Eu lanthanide probe. This advanced technology is designed with exceptional photostability and resistance to ozone, emitting a bright and narrow spectrum of light at 613 nm. The excitation wavelength can be flexibly set between 300-400 nm, and the brightness remains consistent across a wide pH range from 2 to 12. This ability to maintain competitiveness at steady-state with standard fluorophores is enhanced by the unique features of the Lumi804-Eu probe, which offers a long emission lifetime of 716 µs.

Market Potential and Growth

As the NAAT market is projected to grow from $8.1 billion in 2025 to over $16 billion by 2030, this partnership places Synoligo and Lumiphore at the forefront of a rapidly expanding sector. The primary applications currently focus on infectious diseases, but the market is increasingly branching into oncology and genetic testing. Steve Blose, Chief Business Officer of Lumiphore, emphasized that this groundbreaking luminescent oligo detection technology is set to introduce new assays that will serve a wide range of diagnostic needs.

Partnership Overview

Through this partnership, Synoligo has secured non-exclusive rights to incorporate Lumiphore's luminescent technology into its diagnostic tests and research use assays (RUO). This integration is expected to bring numerous advantages to researchers and healthcare professionals, particularly through the simplicity of use and efficiency offered by TR-FRET assays.

Marc Beal, Director of Business Development at Synoligo, commented on the synergy between the two companies, stating, "This potent and unique collaboration explores the use of lanthanides in real-time and time-resolved genomic applications." The combination of expertise from both firms promises to yield innovative solutions vital for molecular diagnostics and life science research.

Conclusion

The collaboration between Synoligo Biotechnologies and Lumiphore marks a pivotal step in the realm of diagnostic technologies. As the NAAT market evolves, it is clear that partnerships such as this one will play an essential role in driving technological advancements and improving healthcare outcomes. For more information about the Lumi804-Eu probe and its applications, visit Synoligo’s website.

This partnership not only strengthens the capabilities of both companies but also underscores their commitment to delivering high-quality, effective solutions that will shape the future of diagnostics and life sciences.